Open: 0.0 Close: 0.0 Change: 0.0

Today's Summary

Sage Therapeutics, Inc. (NASDAQ:SAGE) known for its FDA-approved postpartum depression drug Zurzuvae, is acquired by Supernus Pharmaceuticals in a deal valued at up to $795 million. The agreement, announced in June 2025, includes $561 million in cash and contingent value rights. Modern social media bypasses traditional hierarchies and institutions and gathers together communities of like-minded extremists. It also provides these extremists a platform in which their emotionally charged messages are more likely to go viral.